CRNX
Price
$41.43
Change
-$1.39 (-3.25%)
Updated
Nov 13 closing price
Capitalization
3.93B
110 days until earnings call
Intraday BUY SELL Signals
IDYA
Price
$32.73
Change
+$0.90 (+2.83%)
Updated
Nov 14, 11:58 AM (EDT)
Capitalization
2.79B
137 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRNX vs IDYA

Header iconCRNX vs IDYA Comparison
Open Charts CRNX vs IDYABanner chart's image
Crinetics Pharmaceuticals
Price$41.43
Change-$1.39 (-3.25%)
Volume$1.98M
Capitalization3.93B
IDEAYA Biosciences
Price$32.73
Change+$0.90 (+2.83%)
Volume$989
Capitalization2.79B
CRNX vs IDYA Comparison Chart in %
CRNX
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRNX vs. IDYA commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CRNX: $41.43 vs. IDYA: $31.82)
Brand notoriety: CRNX and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 113% vs. IDYA: 78%
Market capitalization -- CRNX: $3.93B vs. IDYA: $2.79B
CRNX [@Biotechnology] is valued at $3.93B. IDYA’s [@Biotechnology] market capitalization is $2.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 3 bullish, 5 bearish.
  • IDYA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both CRNX and IDYA are a bad buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -4.74% price change this week, while IDYA (@Biotechnology) price change was +6.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.64%. For the same industry, the average monthly price growth was -3.56%, and the average quarterly price growth was +66.73%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 04, 2026.

IDYA is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (+3.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.93B) has a higher market cap than IDYA($2.79B). IDYA YTD gains are higher at: 23.813 vs. CRNX (-18.971). IDYA has higher annual earnings (EBITDA): -380.2M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. IDYA (670M). IDYA has less debt than CRNX: IDYA (26.6M) vs CRNX (49.9M). IDYA has higher revenues than CRNX: IDYA (7M) vs CRNX (1.39M).
CRNXIDYACRNX / IDYA
Capitalization3.93B2.79B141%
EBITDA-419.62M-380.2M110%
Gain YTD-18.97123.813-80%
P/E RatioN/AN/A-
Revenue1.39M7M20%
Total Cash1.2B670M179%
Total Debt49.9M26.6M188%
FUNDAMENTALS RATINGS
CRNX vs IDYA: Fundamental Ratings
CRNX
IDYA
OUTLOOK RATING
1..100
677
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
5662
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
4539
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (27) in the null industry is somewhat better than the same rating for CRNX (86) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (56) in the Pharmaceuticals Major industry is in the same range as IDYA (62) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as IDYA (96) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Price Growth Rating (39) in the null industry is in the same range as CRNX (45) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to CRNX’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXIDYA
RSI
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
76%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMGKX15.88N/A
N/A
Fidelity Magellan K
DFVIX23.86-0.18
-0.75%
DFA International Value III
ADVDX4.84-0.05
-1.02%
abrdn Dynamic Dividend Instl
SSCVX18.10-0.28
-1.52%
Columbia Select Small Cap Value A
WRGCX21.14-0.76
-3.47%
Macquarie Small Cap Growth C

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-3.25%
XNCR - CRNX
59%
Loosely correlated
-2.78%
NUVL - CRNX
54%
Loosely correlated
-2.42%
CLDX - CRNX
53%
Loosely correlated
-2.19%
IDYA - CRNX
53%
Loosely correlated
-0.41%
NRIX - CRNX
52%
Loosely correlated
+2.14%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.41%
NUVL - IDYA
59%
Loosely correlated
-2.42%
NRIX - IDYA
58%
Loosely correlated
+2.14%
XENE - IDYA
58%
Loosely correlated
+0.91%
CGON - IDYA
57%
Loosely correlated
-4.19%
OCUL - IDYA
57%
Loosely correlated
-2.61%
More